Oral water soluble contrast for malignant bowel obstruction
Referencias
Additional references
Abbas S, Bissett IP, Parry BR. Oral water soluble contrast for the management of adhesive small bowel obstruction. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD004651.pub3]
Anthony T, Baron T, Mercadante S, Green S, Chi D, Cunningham J, et al. Report of the Clinical Protocol Committee: development of randomized trials for malignant bowel obstruction. Journal of Pain and Symptom Management July 2007;34(1s):s49‐s59.
Cochrane Pain, Palliative and Supportive Care Group. PaPaS Author and Referee Guidance. http://papas.cochrane.org/papas‐documents 2012 (accessed July 2015).
Brozek J, Oxman A, Schünemann H. GRADEpro Guideline Development Tool [Software]. Version 3.2 for Windows. McMaster University (developed by Evidence Prime, Inc.), 2015.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011] The Cochrane Collaboration. The Cochrane Collaboration, 2011; Vol. Available from www.cochrane‐handbook.org.
Joyce WP, Delaney PV, Gorey TF, Fitzpatrick JM. The value of water‐soluble contrast radiology in the management of acute small bowel obstruction. Annals of the Royal College of Surgeons of England 1992;74:422‐5.
Khasawneh M, Eiken P, Srvantstyan B, Bannon MP, Zielinski MD. Use of the Gastrografin challenge in patients with a history of abdominal or pelvic malignancy. Surgery October 2013;154(4):769‐76.
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collobaration, 2011:Available from www.cochrane‐handbook.org.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine July 2001;6(7):1‐28.
Mercadante S, Ferrera P, Villari P, Marrazzo A. Aggressive pharmacological treatment for reversing malignant bowel obstruction. Journal of Pain and Symptom Management October 2004;28(4):412‐6.
The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.3. Copenhagen: The Cochrane Collaboration, 2014.
Riccabona M. Contrast media use in pediatrics: safety issues. In: Thomsen H, Webb J editor(s). Contrast Media Safety Issues and ESUR Guidelines. 3rd Edition. Springer, 2014:246.
Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, De Conno F, et al. Clinical‐practice recommendations for the management of bowel obstruction in patients with end‐stage cancer. Supportive Care in Cancer June 2001;9(4):223‐33.
Ripamonti C, Bruera E. Palliative management of malignant bowel obstruction. International Journal of Gynaecological Cancer 2002;12:135‐43.
Ripamonti C, Easson A, Gerdes H. Management of malignant bowel obstruction. European Journal of Cancer 2008;44:1105‐15.
Tuca A, Guell E, Martinez‐Losada E, Codorniu N. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Management and Research 2012;4:159‐69.
Vather R, Josephson R, Jaung R, Kahokehr A, Sammour T, Bissett I. Gastrografin in prolonged postoperative ileus: a double‐blinded randomized controlled trial. Annals of Surgery July 2015;262(1):23‐30.
